William K Heiden bought $151k of MGNX
director at MACROGENICS INC. 100,000 shares at an average of $1.51, traded Aug 19, 2025, filed Aug 21, 2025.
Score components
- +15RoleDirector
- +11Trade size$151k at market
- +10Relative to holdingsHoldings up 909%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +12.5%, 3m -4.9%, 6m +20.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001214939-25-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 19, 2025 | POpen-market purchase Common Stock | +50,500 | $1.52 | $77k | 61,500 | Aug 21, 2025 |
| Aug 20, 2025 | POpen-market purchase Common Stock | +49,500 | $1.49 | $74k | 111,000 | Aug 21, 2025 |
Related signals
Other insiders at MACROGENICS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 26Weak | MACROGENICS INC | Jeffrey Stuart Peters Senior VP, GC, and Secretary | $129k 31,105 shares | -100% | |
| 12Weak | MACROGENICS INC | Ezio Bonvini Sr VP, Research & CSO | $190k 18,880 shares | -16% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.